Abstract Library

#2988 Epigenetic Treatment with Histone Deacetylase Inhibitor Enhances Uptake of [111In]In-DOTA-TATE by Increased SST2 Expression on Neuroendocrine Tumor Cells

Introduction: The somatostatin-2 receptor (SST2) is a target for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NETs). By using epigenetic drugs, which can regulate gene transcription, PRRT efficacy may be further improved due to enhanced SST2 expression.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Klomp I

Authors: Klomp I, Dalm S, van Koetsveld P, Dogan-Oruç F, de Jong M,

Keywords: neuroendocrine tumors, bon-1, epigenetic, histone, histone deacetylase inhibitor, HDACi, upregulation, reversibility, somatostatin receptor-2, somatostatin,

#2984 AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy

Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Grötzinger C, Exner S, Schuldt C, Du J, Sachindra S,

Keywords: receptor, targeting, imaging, prrt, peptide, angiotensin,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,

#1850 Influence of VEGF Splicing on Microvessel Density and Architecture in Pancreatic Neuroendocrine Tumours

Introduction: Hypoxia in human tumours is associated with a poor prognosis and is characterized by the stabilization of HIF1α, upregulation of VEGF, and a high microvessel density (MVD). Interestingly, although pancreatic neuroendocrine tumours (pNETS) showing hypoxia signalling also have a poor prognosis, they paradoxically display a low MVD. We hypothesized that this paradoxon might be explained by alternative splicing of VEGF.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Schmitt A

Authors: Marinoni I, Naim S, Centeno I, Perren A, Schmitt A,

Keywords: pNET, VEGF,

#1524 Is mTOR Pathway Activity a Good Predictor for Everolimus Therapy? A Pilot Study to Build Up a Phase II Trial in Pancreatic Neuroendocrine Neoplasias (pNENs)

Introduction: Everolimus (EVE) is an approved treatment for progressive well-differentiated pNENs and usually induces stable disease. Until now, there is no reliable biomarker for the response to EVE.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lock A

Authors: Lock A, Wirtz R, Kaemmerer D, Haugvik S, Kure E,

Keywords: PREDICT-Study, everolimus, pNEN, gene signature, predictive marker,